Alfa-1-antitripsin deficiency and chronic obstrictive pulmonary disease

1. Global strategy for the diagnosis, management and preven tion of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, April 2001; Update of the man agement section, GOLD website (www.goldcopd.com). Date update: September, 2005.

2. Чучалин А.Г. Хроническая обструктивная болезнь легких. (Клинические рекомендации). М.: Изд-во " Атмосфера"; 2003.

3. Cosio M., Ghezzo H., Hogg J.C. et al. The relations between structural changes in small airways and pulmonary function tests. N. Engl. J. Med. 1978; 298: 1277–1281.

4. Lee W.L., Downey G.P. Leukocyte elastase physiological functions and role in acute lung injury. Am. J. Respir. Crit. Care Med. 2001; 164 (5): 896–904.

5. Sommerhoff C.P., Nadel J.A., Basbaum C.B. et al. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J. Clin. Invest. 1990; 85: 682–689.

6. Rodriguez1Roisin R., MacNee W. Pathophysiology of chronic obstructive pulmonary disease. Eur. Respir. Mono. 1998; 3: 107–126.

7. Mercer R., Crapo J.D. Structural changes in elastic fibers after pancreatic elastase administration in hamsters. J. Appl. Physiol. 1992; 72: 1473–1479.

8. Vandivier R.W., Fadok V.A., Hoffmann P.R. et al. Elastase mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J. Clin. Invest. 2002; 109: 661–670.

9. Stockley R.A., Bayley D.L., Unsal I., Dowson L.J. The effect of augmentation therapy on bronchial inflammation in 1 antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 2002; 165: 1494–1498.

10. Carp H., Miller F., Hoidal J.R., Janoff A. Potential mechanism of emphysema: alpha 1 proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methion ine and has decreased elastase inhibitory capacity. Proc. Natl. Acad. Sci. USA 1982; 79: 2041–2045.

11. Taggart C., Cervantes-Laurean D., Kim G. Oxidation of either methionine 351 or methionine 358 in 1 antitrypsin causes loss of anti neutrophil elastase activity. J. Biol. Chem. 2000; 275 (35): 27258–27265.

12. Parmar J.S., Mahadeva R., Reed B.J. Polymers of 1 antit rypsin are chemotactic for human neutrophils. A new para digm for the pathogenesis of emphysema.Am. J. Respir. Cell. Mol. Biol. 2002; 26 (6): 723–730.

13. Mulgrew A.T., Taggart C.C., Lawless M.W. 1 antitrypsin polymerizes in the lung and acts as a neutrophil chemoat tractant. Chest 2004; 125: 1952–1957.

14. Senn O., Russi E.W., Imboden M. alpha1 Antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants. Am. J. Respir. Crit. Care Med. 2000; 161(1): 81–84.

15. De Serres F.J. Worldwide racial and ethnic distribution of alpha1 antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002; 122: 1818–1829.

16. American Thoracic Society. Standards for the diagnosis and management of individuals with alpha 1 antitrypsin defi ciency. Am. J. Respir. Crit Care Med. 2003; 168: 818–900.

17. Пузырев В.П., Савюк В.Я. Молекулярные основы и кли нические аспекты недостаточности α 1 антитрипсина. Пульмонология 2003; 3: 105–115.

18. Hoidal J.R. Genetics of COPD: present and futute. Eur. Respir. J. 2001; 18: 741–743.

19. Laurell C.B., Ericsson S. The electrophoretic alpha1 globu lin pattern of serum in alpha1 antitrypsin deficiency. Scand. J. Clin. Lab. Invest. 1963; 15: 132–140.

20. The Alpha 1 Antitrypsin Deficiency Registry Study Group. Survival and FEV 1 decline in individuals with severe defi ciency of alpha 1 antitrypsin. Am. J. Respir Crit. Care Med. 1998; 158: 49–59.

21. Lieberman J., Winter B., Sastre A. Alpha 1 antitrypsin Pi types in 965 COPD patients. Chest 1986; 89: 370–373.

22. Shigeoka J.W., Hall W.J., Hyde R.W. The prevalence of alpha1 antitrypsin heterozygotes (PiMZ) in patients with obstructive pulmonary disease. Am. Rev. Respir. Dis. 1976; 114: 1077–1084.

23. Самильчук Е.И. Роль наследственных факторов в развитии хронических обструктивных заболеваний органов дыхания: Автореф. дис. д ра. мед. наук. М.; 1997.

24. Guest P.J., Hansell D.M. High resolution computed tomog raphy (HRCT) in emphysema associated with alpha 1 antitrypsin deficiency. Clin. Radiol. 1992; 45: 260–266.

25. King M.A., Stone J.A., Diaz P.T. et al. Alpha 1 antitrypsin deficiency: evaluation of bronchiectasis with CT. Radiology 1996; 199: 137–141.

26. Shin M.S., Ho K.J. Bronchiectasis in patients with alpha 1 antitrypsin deficiency. A rare occurrence? Chest 1993; 104: 1384–1386.

27. Cuvelier A., Muir J.1F., Hellot M.1F. et al. Distribution of {alpha}1 antitrypsin alleles in patients with bronchiectasis. Chest 2000; 117(2): 415–419.

28. Eden E., Hammel J., Rouhani F.N. Asthma features in severe {alpha}1 antitrypsin deficiency: Experience of the National Heart, Lung, and Blood Institute Registry. Chest 2003; 123 (3): 765–771.

29. Eden E., Mitchell D., Mehlman B. et al. Atopy, asthma, and emphysema in patients with severe alpha 1 antitrypsin defi ciency. Am. J. Respir. Crit. Care Med. 1997; 156: 68–74.

30. Tashkin D.P., Altose M.D., Bleecker E.R. et al. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation; The Lung Health Study Research Group. Am. Rev. Respir. Dis. 1992; 145: 301–310.

31. World Health Organization. 1 Antitrypsin deficiency: Memorandum from a WHO meeting. Bull. Wld. Hlth. Org.1997; 75: 397–415.

32. Bense L., Lewander R., Eklund G. et al. Nonsmoking, non alpha 1 antitrypsin deficiency induced emphysema in non smokers with healed spontaneous pneumothorax, identified by computed tomography of the lungs. Chest 1993; 103: 433–438.

33. Henry M., Arnold T., Harvey J. BTS guidelines for the man agement of spontaneous pneumothorax.Thorax. 2003; 58 (suppl. 2): 39–52.

34. Чучалин А.Г., Кронина Л.А., Воронина Л.М., Самильчук Е.И. Случай сочетания муковисцидоза с дефицитом альфа 1 антитрипсина. Пульмонология 1994; 3: 82–84.

35. Seersholm N., Wencker M., Banik N. et al. Does alpha 1 antitrypsin augmentation therapy slow the annual decline in FEV 1 in patients with severe hereditary alpha 1 antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1 AT study group. Eur. Respir. J. 1997; 10: 2260–2263.

36. Wencker M., Fuhrmann B., Banik N. et al. Longitudinal fol low up of patients with alpha(1) protease inhibitor defi ciency before and during therapy with IV alpha(1) protease inhibitor. Chest 2001; 119: 737–744.

37. Strange C., Dickson R., Cartier C. et al. Survival and FEV1 decline in individuals with severe deficiency of alpha 1 antitrypsin. The Alpha 1 Antitrypsin Deficiency Registry Study Group. Am. J. Respir. Crit. Care Med. 1998; 158: 49–59.

38. Chapman K.R., Stockley R.A., Dawkins C. et al. Augmen tation therapy for α 1 antitrypsin deficiency: a meta analysis of randomized and non randomized clinical studies. Eur. Respir. J. 2005; 26 (49): 288.

39. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118: 1480–1485.

40. Gottlieb D.J., Luisetti M., Stone P.J. et al. Short term supplementation therapy does not affect elastin degradation in severe 1 antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 2000; 162: 2069–2072.

41. Дидковский Н.А., Лебедев Ю.А. Наследственный дефицит альфа 1 антитрипсина и хронические неспецифические заболевания легких. Тер. арх. 1974; 11: 30–33.